Bretschneider (Custodiol®) and St. Thomas 2 Cardioplegia Solution in Mitral Valve Repair via Anterolateral Right Thoracotomy: A Propensity-Modelled Comparison.


Journal

Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001

Informations de publication

Date de publication:
2019
Historique:
received: 30 08 2019
accepted: 12 11 2019
entrez: 31 12 2019
pubmed: 31 12 2019
medline: 9 6 2020
Statut: epublish

Résumé

Single-dose cardioplegia is preferred in minimal invasive mitral valve surgery to maintain the adjustment of the operative site without change of preset visualization. The aim of our study was to compare two widely used crystalloid cardioplegias Bretschneider (Custodiol®) versus St. Thomas 2 in patients who underwent mitral valve repair via small anterolateral right thoracotomy. From May 2012 until February 2019, 184 isolated mitral valve procedures for mitral valve repair via anterolateral right thoracotomy were performed using Bretschneider (Custodiol®) cardioplegia ( Peak hs-cTnT was higher after use of Bretschneider (Custodiol®) (geometric mean 716 mg/L, 95% confidence interval (CI) 605-847 mg/L) vs. St. Thomas 2 (561 mg/L, CI 467-674 mg/L, Use of St. Thomas 2 cardioplegia was associated with lower postoperative peak levels of all cardiac markers that reflect cardiac ischemia such as hs-cTnT, CK, and CK-MB as compared to Bretschneider (Custodiol®) in propensity-weighted treatment groups.

Sections du résumé

BACKGROUND BACKGROUND
Single-dose cardioplegia is preferred in minimal invasive mitral valve surgery to maintain the adjustment of the operative site without change of preset visualization. The aim of our study was to compare two widely used crystalloid cardioplegias Bretschneider (Custodiol®) versus St. Thomas 2 in patients who underwent mitral valve repair via small anterolateral right thoracotomy.
MATERIAL AND METHODS METHODS
From May 2012 until February 2019, 184 isolated mitral valve procedures for mitral valve repair via anterolateral right thoracotomy were performed using Bretschneider (Custodiol®) cardioplegia (
RESULTS RESULTS
Peak hs-cTnT was higher after use of Bretschneider (Custodiol®) (geometric mean 716 mg/L, 95% confidence interval (CI) 605-847 mg/L) vs. St. Thomas 2 (561 mg/L, CI 467-674 mg/L,
CONCLUSION CONCLUSIONS
Use of St. Thomas 2 cardioplegia was associated with lower postoperative peak levels of all cardiac markers that reflect cardiac ischemia such as hs-cTnT, CK, and CK-MB as compared to Bretschneider (Custodiol®) in propensity-weighted treatment groups.

Identifiants

pubmed: 31885497
doi: 10.1155/2019/5648051
pmc: PMC6914981
doi:

Substances chimiques

Bretschneider cardioplegic solution 0
Cardioplegic Solutions 0
Mannitol 3OWL53L36A
Procaine 4Z8Y51M438
Potassium Chloride 660YQ98I10
Glucose IY9XDZ35W2

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5648051

Informations de copyright

Copyright © 2019 Constantin Mork et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

PeerJ. 2018 May 28;6:e4810
pubmed: 29868261
Thorac Cardiovasc Surg. 1980 Oct;28(5):295-302
pubmed: 6161427
Thorac Cardiovasc Surg. 1984 Oct;32(5):271-6
pubmed: 6083614
Artif Organs. 2017 May;41(5):470-475
pubmed: 27878830
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
Bioelectrochemistry. 2019 Feb;125:58-69
pubmed: 30265864
Ann Thorac Surg. 1996 Jan;61(1):67-75
pubmed: 8561641
Heart Lung Circ. 2014 Sep;23(9):863-8
pubmed: 24767979
Innovations (Phila). 2016 Nov/Dec;11(6):420-424
pubmed: 27879532
Eur J Cardiothorac Surg. 2016 Nov;50(5):787-791
pubmed: 27369117
Thorac Cardiovasc Surg. 2016 Jan;64(1):53-8
pubmed: 26600405
Thorac Cardiovasc Surg. 1988 Jun;36(3):151-6
pubmed: 3145585
Heart. 2019 May;105(10):783-789
pubmed: 30541760

Auteurs

Constantin Mork (C)

Department of Cardiac Surgery, University Hospital Basel, Basel, Switzerland.

Luca Koechlin (L)

Department of Cardiac Surgery, University Hospital Basel, Basel, Switzerland.

Thibault Schaeffer (T)

Department of Cardiac Surgery, University Hospital Basel, Basel, Switzerland.

Lena Schoemig (L)

Department of Cardiac Surgery, University Hospital Basel, Basel, Switzerland.

Urs Zenklusen (U)

Department of Cardiac Surgery, University Hospital Basel, Basel, Switzerland.

Brigitta Gahl (B)

Department of Cardiac Surgery, University Hospital Basel, Basel, Switzerland.

Oliver Reuthebuch (O)

Department of Cardiac Surgery, University Hospital Basel, Basel, Switzerland.

Friedrich S Eckstein (FS)

Department of Cardiac Surgery, University Hospital Basel, Basel, Switzerland.

Martin T R Grapow (MTR)

Department of Cardiac Surgery, University Hospital Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH